Community Oncology Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy – Strategies for the Multidisciplinary Team | South Carolina

Release Date: November 24, 2025

Expiration Date: December 29, 2025

Activity Overview

The management of advanced melanoma continues to evolve rapidly, with oncolytic immunotherapies emerging as pivotal, tailored treatment options. Despite these advancements, challenges with integrating these therapies into multidisciplinary clinical practice remain at the forefront.

This live, virtual symposium brings together an expert in the management of melanoma with a local community oncologist to discuss the importance of multidisciplinary collaborative care and features real-world, practical, case-based discussions to optimize treatment sequencing and selection in the care of patients with advanced melanoma. A focus on understanding resistance to first-line therapies and exploring advanced therapeutic strategies (eg, oncolytic viruses, combination immunotherapies) helps practicing clinicians navigate the complexities of advanced melanoma treatment. The interactive case-based discussions provide participants with actionable strategies for lesion prioritization and evaluation and procedural workflow integration; it also offers insight into evidence-based decision-making to help inform treatment selection. By incorporating the latest clinical trial data, the program offers insights into the efficacy, safety, and real-world application of these innovative therapies to advance personalized care and optimize outcomes for patients with advanced melanoma.

This educational activity is an archive of the Community Oncology Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy – Strategies for the Multidisciplinary Team presentation held on November 13, 2025.

Target Audience

This educational program is directed toward community-based medical oncologists, interventional radiologists, surgeons, nurse practitioners, nurses, pharmacists, and other health care professionals involved in the treatment of advanced melanoma.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Evaluate clinical and safety data for second-line therapies in melanoma, including oncolytic viruses, tumor-infiltrating lymphocytes, and combination immunotherapies, in patients with progression on PD-1 inhibitors.
• Describe the mechanistic rationale, administration techniques, and clinical benefits of oncolytic viruses in advanced melanoma.
• Apply best practices for the multidisciplinary care of patients receiving intratumoral oncolytic immunotherapies, including coordination between medical oncologists, interventional radiologists, nurse practitioners, nurses, pharmacists, and surgical oncologists.